Jazz Pharmaceuticals (JAZZ) announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz’s President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company’s next leader. Cozadd will continue to serve as Chairperson of the Board.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- 3 Must-Watch Stocks with a ‘Perfect 10’ Smart Score
- Jazz Pharmaceuticals’ Promising Study on Zanidatamab for HER2-positive Breast Cancer
- Jazz Pharmaceuticals’ New Study on Zanidatamab: A Potential Game-Changer in Breast Cancer Treatment?
- Jazz Pharmaceuticals says EC grants marketing authorization for Ziihera
- Jazz Pharmaceuticals’ Pregnancy Surveillance Study: A Key Update for Investors